CoChat

Leveraging speech and artificial intelligence to screen for early Alzheimer's disease and amyloid beta positivity

Open access

The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.

Abstract

Early detection of Alzheimer’s disease is required to identify patients suitable for disease-modifying medications and to improve access to non-pharmacological preventative interventions. Prior research shows detectable changes in speech in Alzheimer’s dementia and its clinical precursors. The current study assesses whether a fully automated speech-based artificial intelligence system can detect cognitive impairment and amyloid beta positivity, which characterize early stages of Alzheimer’s disease. Two hundred participants (age 54–85, mean 70.6; 114 female, 86 male) from sister studies in the UK (NCT04828122) and the USA (NCT04928976), completed the same assessments and were combined in the current analyses. Participants were recruited from prior clinical trials where amyloid beta status (97 amyloid positive, 103 amyloid negative, as established via PET or CSF test) and clinical diagnostic status was known (94 cognitively unimpaired, 106 with mild cognitive impairment or mild Alzheimer’s disease). The automatic story recall task was administered during supervised in-person or telemedicine assessments, where participants were asked to recall stories immediately and after a brief delay. An artificial intelligence text-pair evaluation model produced vector-based outputs from the original story text and recorded and transcribed participant recalls, quantifying differences between them. Vector-based representations were fed into logistic regression models, trained with tournament leave-pair-out cross-validation analysis to predict amyloid beta status (primary endpoint), mild cognitive impairment and amyloid beta status in diagnostic subgroups (secondary endpoints). Predictions were assessed by the area under the receiver operating characteristic curve for the test result in comparison with reference standards (diagnostic and amyloid status). Simulation analysis evaluated two potential benefits of speech-based screening: (i) mild cognitive impairment screening in primary care compared with the Mini-Mental State Exam, and (ii) pre-screening prior to PET scanning when identifying an amyloid positive sample. Speech-based screening predicted amyloid beta positivity (area under the curve = 0.77) and mild cognitive impairment or mild Alzheimer’s disease (area under the curve = 0.83) in the full sample, and predicted amyloid beta in subsamples (mild cognitive impairment or mild Alzheimer’s disease: area under the curve = 0.82; cognitively unimpaired: area under the curve = 0.71). Simulation analyses indicated that in primary care, speech-based screening could modestly improve detection of mild cognitive impairment (+8.5%), while reducing false positives (−59.1%). Furthermore, speech-based amyloid pre-screening was estimated to reduce the number of PET scans required by 35.3% and 35.5% in individuals with mild cognitive impairment and cognitively unimpaired individuals, respectively. Speech-based assessment offers accessible and scalable screening for mild cognitive impairment and amyloid beta positivity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/braincomms/fcac231

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1 Participant selection. (A) Participant inclusion criteria: participants were included based on prior amyloid status and clinical diagnosis confirmation. (B) Participant flow diagram, documenting exclusions, and dropouts during study recruitment. MCI, mild cognitive impairment; AD, Alzheimer’s disease; MMSE, Mini-Mental State Exam; n, number.
Figure 1 Participant selection. (A) Participant inclusion criteria: participants were included based on prior amyloid status and clinical diagnosis confirmation. (B) Participant flow diagram, documenting exclusions, and dropouts during study recruitment. MCI, mild cognitive impairment; AD, Alzheimer’s disease; MMSE, Mini-Mental State Exam; n, number.CC BY · PubMed Central
Figure 2 ROC curves for the ASRT system and comparison models. AUCs and 95% confidence intervals for the classifiers predicting: (A) amyloid positivity and (B) mild cognitive impairment (MCI)/mild Alzheimer’s disease in the full sample. Subsample comparisons of classifier performance predicting (C) amyloid positivity within the MCI/mild Alzheimer’s disease; and (D) amyloid positivity in the CU sample. The table below each figure provides sensitivity (Sn) and specificity (Sp) at Youden’s index and Cohen’s kappa (Cohen K). The reference test was biomarker confirmation from PET or CSF for A, C, and D. Reference test was clinical diagnosis for B. The demographic comparison includes age, sex and education level. AD, Alzheimer’s disease; ASRT, automatic story recall test; PACC5, preclinical Alzheimer’s cognitive composite with semantic processing; ROC, receiver operator characteristic; AUC, area under the curve.
Figure 2 ROC curves for the ASRT system and comparison models. AUCs and 95% confidence intervals for the classifiers predicting: (A) amyloid positivity and (B) mild cognitive impairment (MCI)/mild Alzheimer’s disease in the full sample. Subsample comparisons of classifier performance predicting (C) amyloid positivity within the MCI/mild Alzheimer’s disease; and (D) amyloid positivity in the CU sample. The table below each figure provides sensitivity (Sn) and specificity (Sp) at Youden’s index and Cohen’s kappa (Cohen K). The reference test was biomarker confirmation from PET or CSF for A, C, and D. Reference test was clinical diagnosis for B. The demographic comparison includes age, sex and education level. AD, Alzheimer’s disease; ASRT, automatic story recall test; PACC5, preclinical Alzheimer’s cognitive composite with semantic processing; ROC, receiver operator characteristic; AUC, area under the curve.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 2

  1. Wechsler, 2008, WAIS-R Manual: Wechsler Adult Intelligence Scale-Revised
  2. Liu, 2019, RoBERTa: A robustly optimised BERT pretraining approach, arXiv

Cited by

See all 31

Metadata

Authors
Fristed, E., Skirrow, C., Meszaros, M., Lenain, R., Meepegama, U., Papp, K. V., Ropacki, M., & Weston, J.
Affiliations
  • Novoic Ltd , London, N1 7EU , UK
  • Brigham and Women's Hospital (US)
  • Strategic Global Research & Development , Temecula, California, 94019 , USA
Corresponding author
Skirrow, Caroline
Venue
Brain Communications
Published
2022-09-01
Volume
4
Issue
5
Pages
fcac231-fcac231
ISSN
2632-1297 (ISSN-L)
OpenAlex
W4306403642
Cited by
29
References
55
Citations by year
2026: 9 · 2025: 10 · 2024: 8 · 2023: 2
FWCI
3.26
Type
journal article
Language
en
Open access
Locations
  • Brain Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Bristol Research (University of Bristol) (submittedVersion, cc-by)
  • Explore Bristol Research (submittedVersion, cc-by)
Funders
Novoic
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
Keywords
Alzheimer's disease, automated speech analysis, artificial intelligence, mild cognitive impairment, early detection, story recall, primary care screening, telemedicine, cognitive screening, false positives

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.